Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 May 1;64(5):2496-2504.
doi: 10.1093/rheumatology/keae599.

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Yann Nguyen  1   2 , Gabriel Baron  3 , Naima Hamamouche  4 , Rakiba Belkhir  1 , Sylvie Miconnet  1 , Martin Soubrier  5 , Camille Hostachy  1 , Pascale Thevenot  6 , André Basch  7 , Marie-Elise Truchetet  8 , Pascal Claudepierre  9 , Emmanuelle Dernis  10 , Hubert Marotte  11 , René-Marc Flipo  12 , Olivier Brocq  13 , Jacques Morel  14 , Bruno Fautrel  15 , Carine Salliot  16 , Alain Saraux  17 , Charles Leske  18 , Thierry Schaeverbeke  19 , Philippe Ravaud  3 , Xavier Mariette  1   2 , Adeline Ruyssen-Witrand  20 , Raphaèle Seror  1   2 ; ART Study Group§
Collaborators, Affiliations
Randomized Controlled Trial

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Yann Nguyen et al. Rheumatology (Oxford). .

Abstract

Objectives: The objectives of this study were to evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among RA patients treated with anti-TNF therapies, and to identify factors associated with vaccination.

Methods: This study was a nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age. The intervention consisted of regular reminders via SMS and/or emails to get vaccinated against influenza during the vaccination campaign. At the end, all participants received a questionnaire. The primary outcome was influenza vaccination coverage. Secondary outcomes included the vaccination coverage before and after the COVID-19 pandemic, and factors associated with vaccination.

Results: Between October 2021 and April 2022, 446 participants were randomized (224 to the intervention group and 222 to the control group). Among them, 325 (73%) reported their vaccination status and 221 (68%) were vaccinated against influenza: 116/158 (73%) in the intervention group, vs 105/167 (63%) in the control group (relative risk 1.08; 95% CI 0.95-1.23). The vaccination coverage before and after the COVID-19 pandemic did not differ (72% vs 72%; 95% CI -8% to 8%). Age ≥65 years [odds ratio (OR) 6.25; 95% CI 2.88-13.60] and previous influenza vaccination in the years before inclusion (OR 7.81; 95% CI 4.36-14.02) were associated with higher rates of vaccination.

Conclusion: SMS and/or e-mail reminders did not significantly improve influenza vaccination rates in our cohort. The COVID-19 pandemic did not substantially impact the influenza vaccination coverage. Our results might be counterbalanced by an already high vaccination coverage.

Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT05220423, NCT03062865.

Keywords: bDMARDs; influenza; rheumatoid arthritis; vaccine.

PubMed Disclaimer

Publication types

MeSH terms

Associated data